Glofitamab in Chinese Patients With R/R DLBCL

Recruiting now

Conditions studied: DLBCL - Diffuse Large B Cell Lymphoma

In brief

This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.

Key facts

Study ID

NCT06481826

Run by

Peking Union Medical College Hospital

People needed

20

Starts

2024-01-01

Expected to finish

2028-12-31

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-confirmed DLBCL
• Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy
• Participants must have measurable disease

You may not qualify if…

• Pregnancy or breastfeeding
• Patient with known active infection, or reactivation of a latent infection
• Patient with active autoimmune disease or immune deficiency
• severe organ failure：LVEF<40%；DLCO<40%；eGFR<30ml/min；Bilirubin≥3ULN
• Patients who are dependent on the sponsor, the investigator or the trial site

Where it is running

• Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.